Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07023224 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2025 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jul 31, 2025 to Nov 30, 2025
    • Study completion date: Aug 2025 to Dec 1, 2025
    • Site details revised at 2 of 2 sites
    v3
  2. Enrollment target: 67 to 130
    • Site details revised at 2 of 2 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this methodological study was to investigate the Turkish validity and reliability of the Parkinson's Disease Dyskinesia Scale (PDYS-26).The scale evaluates choreic dyskinesia.Measures the impact of dyskinesia on activities of daily living in patients with Parkinson's disease. Hypotheses of the Study: * Parkinson's Disease Dyskinesia Scale (PDYS-26) is reliable in Turkish. * Parkinson's Disease Dyskinesia Scale (PDYS-26) is valid in Turkish. To determine the validity of dyskinesia; * Tampa Kinesiophobia Scale, * Mini BesTest, * Activity Specific Balance Safety Scale (ABC) and * Parkinson's Disease Questionnaire-39 will be evaluated.
Trial Details
NCT Number NCT07023224
Lead Sponsor Izmir Bakircay University
Conditions
(from sponsor)		 Idiopathic Parkinson Disease, Dyskinesias, Quality of Life
Related terms Dyskinesias, Parkinson Disease
Enrollment 130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov